Trastuzumab biosimilar (Shanghai Henlius Biotech)

曲妥珠单抗生物类似药（复宏汉霖生物）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTrastuzumab biosimilar (Shanghai Henlius Biotech)
Drug Alias Nametrastuzumab biosimilar曲妥珠单抗生物仿制药（复宏汉霖生物）Zercepac汉曲优HERCESSI +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast NeoplasmsNeoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaStomach NeoplasmsBreast Neoplasms
Original Approved Country/TerritoryEU
Original Approved Date2020/07/27
Country/TerritoryCanadaUnited StatesUkraine +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesCipla Australia Pty LtdMabxience SaAccord Healthcare Slu +[9] 
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XC03
Related LinksN/A